Biologic Drug Prices Why They’re High and Will They Drop?

Explore why biologic drug prices are so high and whether Trump’s plans to speed up biosimilar approvals could make these life-saving medications more affordable for patients.
Biologic drugs are among the most innovative treatments in modern medicine — but they’re also some of the most expensive. As the Trump administration pushes to speed up biosimilar approvals, many Americans are asking whether these policy changes will actually make medications more affordable.

What Are Biologics?

Biologics are advanced medicines created from living cells rather than chemical compounds. This category includes insulin, vaccines, gene therapies, and treatments for cancer and autoimmune diseases. Because they are complex and sensitive, biologics are usually given by injection or intravenous infusion.

These drugs take 10–15 years to develop and require highly specialized manufacturing, which is one reason their prices are so high.

What Are Biosimilars?

Biosimilars are the follow-up products to biologics — similar in function and effect but not identical. Once a biologic’s patent expires, other drugmakers can create biosimilars such as the Humira alternatives Amjevita, Cyltezo, and Idacio.

Unlike traditional generics, biosimilars cannot be exact copies because biologics themselves are complex, protein-based molecules. Still, the FDA requires biosimilars to demonstrate:

• No meaningful differences in safety or effectiveness
• Highly similar structure and performance
• Comparable side-effect profiles

Approval typically takes five to six years, shorter than the timeline for a new biologic.

Why Do Biologic Drugs Cost So Much?

Biologics are expensive for several reasons:

1. Extremely Complex Manufacturing

Creating a biologic often involves genetically engineering living organisms — far more complicated than mixing chemical ingredients to make pills like aspirin.

2. Costly Research and Long Development Timelines

Years of clinical testing, regulation, and quality control can cost billions.

3. Limited Market Competition

As of mid-2025, the U.S. had only 76 approved biosimilars compared with more than 32,000 generic drugs. Fewer competitors mean higher prices.

4. Patent “Thickets”

Brand-name biologic companies often hold dozens of overlapping patents, allowing them to block biosimilars through lengthy legal battles.

How Much Do Biologics and Biosimilars Cost?

Prices vary widely, but many biologics cost $10,000–$30,000 per year.

• Humira was listed at nearly $7,000 for a one-month supply in late 2025.
• Biosimilars are typically 15%–35% cheaper, though some discount versions can cost far less when purchased directly.

Out-of-pocket costs depend heavily on insurance coverage and negotiated rates.

Can Biosimilars Replace Original Biologics?

Yes. Once approved by the FDA, biosimilars are considered just as safe and effective as the original biologic. Doctors can prescribe them with confidence, and in many cases pharmacists can substitute them when allowed by state law.

What Is Trump Proposing to Change?

The Trump administration wants to streamline the FDA approval process for biosimilars. A key proposal is to remove the requirement for comparative clinical trials — expensive head-to-head studies that prove similarity using large patient samples.

Instead, biosimilar makers could rely more on:

• Analytical testing
• Immune-response data
• Small human studies showing how the drug moves through the body

The goal is to cut unnecessary costs and speed up competition.

Will Trump’s Plan Reduce Drug Prices?

The answer: maybe — but not immediately.

Potential Benefits

• Lower development costs for biosimilar companies
• Faster availability of alternatives
• More competition over time

Real-World Challenges

However, several obstacles could blunt the price impact:

1. Rebate Walls: Brand-name drug companies offer large rebates to pharmacy benefit managers (PBMs). In exchange, insurers favor the biologic over its cheaper biosimilars, limiting patient access.
2. Slow Market Adoption: Even when biosimilars exist, they don’t always get prescribed or placed on insurance formularies.
3. Patent Lawsuits: Legal barriers can delay biosimilars for years, even after FDA approval.

A 2024 study found that many patients did not see lower out-of-pocket costs, even when switching to a biosimilar.

What Needs to Change for Prices to Fall?

Beyond regulatory updates, experts say the U.S. needs:

• More transparency in PBM rebate practices
• Faster resolution of patent disputes
• Stronger incentives for insurers to cover low-cost biosimilars
• Education for doctors and patients to build trust in biosimilars

Final Thoughts

Biosimilars have the potential to dramatically reduce healthcare spending, but regulation alone won’t guarantee lower prices. Trump’s proposals could accelerate competition, yet entrenched industry practices — especially rebates and patent strategies — may continue to keep costs high unless broader reforms follow.